1.
Indian J Dermatol Venereol Leprol
; : 1-4, 2024 May 06.
Article
in English
| MEDLINE
| ID: mdl-38841943
2.
Pediatr Dermatol
; 41(1): 139-140, 2024.
Article
in English
| MEDLINE
| ID: mdl-37495552
ABSTRACT
Atopic dermatitis (AD) is predominantly mediated by a T-helper 2 immune system response. While JAK inhibitors have gained treatment approval for AD, data regarding interclass efficacy and therapeutic rationale is lacking. We report a patient with recalcitrant AD who failed baricitinib but demonstrated an excellent response to the pan-JAK inhibitor tofacitinib.
Subject(s)
Azetidines , Dermatitis, Atopic , Janus Kinase Inhibitors , Purines , Pyrazoles , Pyrimidines , Sulfonamides , Humans , Janus Kinase Inhibitors/therapeutic use , Dermatitis, Atopic/drug therapy , Piperidines/therapeutic use , Treatment Outcome
3.
4.
Indian J Dermatol Venereol Leprol
; 88(1): 132, 2021.
Article
in English
| MEDLINE
| ID: mdl-34491670